Recent Updates
Recently added Catalysts
MCK

SUPPLEMENTAL HISTORICAL SEGMENT FINANCIAL INFORMATION We are furnishing to investors supplemental historical financial information by new reportable segment for our quarterly and annual results of fiscal 2018 as well as

Key Takeaway: SUPPLEMENTAL HISTORICAL SEGMENT FINANCIAL INFORMATION We are furnishing to investors supplemental historical financial information by new reportable segment for our quarterly and annual results of fiscal 2018 as well as annual results for fiscal 2017 and 2016. We believe the pre

Full Press Release Details

SUPPLEMENTAL HISTORICAL SEGMENT FINANCIAL INFORMATION
We are furnishing to investors supplemental historical financial information by new reportable segment for our quarterly and annual results of fiscal 2018 as well as annual results for fiscal 2017 and 2016. We believe the presentation of our historical segment financial information by new reportable segment provides useful supplemental information to investors to better understand the impact of segment changes.
Exhibit I: provides a reconciliation of the Company s previously reported GAAP segment financial results to Adjusted Earnings (Non-GAAP) supplemental to our quarterly and annual results of fiscal 2018 as well as annual results for fiscal 2017 and 2016.
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION
In an effort to provide investors with additional information regarding the Company s financial results as determined by generally accepted accounting principles ( GAAP ), McKesson Corporation (the Company or we ) also presents the following Non-GAAP measures in this press release. The Company believes the presentation of Non-GAAP measures provides useful supplemental information to investors with regard to its operating performance, as well as assists with the comparison of its past financial performance to the Company s future financial results. Moreover, the Company believes that the presentation of Non-GAAP measures assists investors ability to compare its financial results to those of other companies in the same industry. However, the Company s Non-GAAP measures used in the press tables may be defined and calculated differently by other companies in the same industry.
Amortization of acquisition-related intangibles - Amortization expenses of intangible assets directly related to business combinations and/or the formation of joint ventures and equity method investments.
Acquisition-related expenses and adjustments - Transaction, integration and other expenses that are directly related to business combinations, the formation of joint ventures and the Healthcare Technology Net Asset Exchange. Examples include transaction closing costs, professional service fees, legal fees, restructuring or severance charges, retention payments and employee relocation expenses, facility or other exit-related expenses, certain fair value adjustments including deferred revenues, contingent consideration and inventory, recoveries of acquisition-related expenses or post-closing expenses, bridge loan fees, gains or losses related to foreign currency contracts entered into directly due to acquisitions, gains or losses on business combinations, and gain on the Healthcare Technology Net Asset Exchange.
LIFO inventory-related adjustments - LIFO inventory-related non-cash expense or credit adjustments.
Gains from antitrust legal settlements - Net cash proceeds representing the Company s share of antitrust lawsuit settlements.
Restructuring charges - Non-acquisition related restructuring charges that are incurred for programs in which we change our operations, the scope of a business undertaken by our business units, or the manner in which that business is conducted. Such charges may include employee severance, retention bonuses, facility closure or consolidation costs, lease or contract termination costs, asset impairments, accelerated depreciation and amortization, and other related expenses. The restructuring programs may be implemented due to the sale or discontinuation of a product line, reorganization or management structure changes, headcount rationalization, realignment of operations or products, and/or Company-wide cost saving initiatives. The amount and/or frequency of these restructuring charges are not part of our underlying business, which includes normal levels of reinvestment in the business. Any credit adjustments due to subsequent changes in estimates are also excluded. These restructuring charges are reflected under various captions within our operating expenses.
Other adjustments - The Company evaluates the nature and significance of transactions qualitatively and quantitatively on an individual basis and may include them in the determination of our Adjusted Earnings from time to time. While not all-inclusive, other adjustments may include: gains or losses from divestitures of businesses that do not qualify as discontinued operations and from dispositions of assets; asset impairments; adjustments to claim and litigation reserves for estimated probable losses; certain discrete benefits related to the December 2017 enactment of the 2017 Tax Cuts and Jobs Act; gains or losses from debt extinguishment; and other similar substantive and/or infrequent items as deemed appropriate.
Income taxes on Adjusted Earnings are calculated in accordance with Accounting Standards Codification ( ASC ) 740, Income Taxes, which is the same accounting principle used by the Company when presenting its GAAP financial results.
Additionally, our equity method investments financial results are adjusted for the above noted items.
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION (continued)
The Company internally uses Non-GAAP financial measures in connection with its own financial planning and reporting processes. Specifically, Adjusted Earnings serves as one of the measures management utilizes when allocating resources, deploying capital and assessing business performance and employee incentive compensation. The Company conducts its business internationally in local currencies, including Euro, British pound sterling and Canadian dollars. As a result, the comparability of our results reported in U.S. dollars can be affected by changes in foreign currency exchange rates. We present constant currency information to provide a framework for assessing how our business performed excluding the estimated effect of foreign currency exchange rate fluctuations. Nonetheless, Non-GAAP financial results and related measures disclosed by the Company should not be considered a substitute for, nor superior to, financial results and measures as determined or calculated in accordance with GAAP.
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP) SUPPLEMENTAL
FOR FISCAL YEAR AND FISCAL QUARTERS OF 2018
Quarter Ended June 30, 2017 Quarter Ended September 30, 2017 Quarter Ended December 31, 2017 Quarter Ended March 31, 2018 Year Ended March 31, 2018
As Reported (GAAP) Adjustments Adjusted Earnings (Non-GAAP) As Reported (GAAP) Adjustments Adjusted Earnings (Non-GAAP) As Reported (GAAP) Adjustments Adjusted Earnings (Non-GAAP) As Reported (GAAP) Adjustments Adjusted Earnings (Non-GAAP) As Reported (GAAP) Adjustments Adjusted Earnings (Non-GAAP)
REVENUES
U.S. Pharmaceutical and Specialty Solutions $ 40,282 $ $ 40,282 $ 40,603 $ $ 40,603 $ 41,969 $ $ 41,969 $ 39,733 $ $ 39,733 $ 162,587 $ $ 162,587
European Pharmaceutical Solutions 6,382 6,382 6,773 6,773 6,989 6,989 7,176 7,176 27,320 27,320
Medical-Surgical Solutions 1,533 1,533 1,660 1,660 1,693 1,693 1,725 1,725 6,611 6,611
Other (1) 2,854 2,854 3,025 3,025 2,966 2,966 2,994 2,994 11,839 11,839
Revenues $ 51,051 $ $ 51,051 $ 52,061 $ $ 52,061 $ 53,617 $ $ 53,617 $ 51,628 $ $ 51,628 $ 208,357 $ $ 208,357
OPERATING PROFIT
U.S. Pharmaceutical and Specialty Solutions $ 475 $ 54 $ 529 $ 710 $ (40 ) $ 670 $ 565 $ 40 $ 605 $ 785 $ (23 ) $ 762 $ 2,535 $ 31 $ 2,566
European Pharmaceutical Solutions 35 49 84 (547 ) 636 89 16 69 85 (1,185 ) 1,267 82 (1,681 ) 2,021 340
Medical-Surgical Solutions 108 17 125 118 18 136 123 18 141 112 30 142 461 83 544
Other (1) (2) 17 214 231 74 167 241 180 33 213 (378 ) 621 243 (107 ) 1,035 928
Operating profit 635 334 969 355 781 1,136 884 160 1,044 (666 ) 1,895 1,229 1,208 3,170 4,378
Corporate (109 ) (3 ) (112 ) (108 ) 15 (93 ) (120 ) 13 (107 ) (227 ) 21 (206 ) (564 ) 46 (518 )
Income from continuing operations before interest expense and income taxes $ 526 $ 331 $ 857 $ 247 $ 796 $ 1,043 $ 764 $ 173 $ 937 $ (893 ) $ 1,916 $ 1,023 $ 644 $ 3,216 $ 3,860
OPERATING PROFIT AS A % OF REVENUES
U.S. Pharmaceutical and Specialty Solutions 1.18 % 1.31 % 1.75 % 1.65 % 1.35 % 1.44 % 1.98 % 1.92 % 1.56 % 1.58 %
European Pharmaceutical Solutions 0.55 1.32 (8.08 ) 1.31 0.23 1.22 (16.51 ) 1.14 (6.15 ) 1.24
Medical-Surgical Solutions 7.05 8.15 7.11 8.19 7.27 8.33 6.49 8.23 6.97 8.23
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP) SUPPLEMENTAL
FOR FISCAL 2016 - 2017
Year Ended March 31, 2017 Year Ended March 31, 2016
As Reported (GAAP) Adjustments Adjusted Earnings (Non-GAAP) As Reported (GAAP) Adjustments Adjusted Earnings (Non-GAAP)
REVENUES
U.S. Pharmaceutical and Specialty Solutions $ 155,236 $ $ 155,236 $ 149,222 $ $ 149,222
European Pharmaceutical Solutions 24,847 24,847 23,497 23,497
Medical-Surgical Solutions 6,244 6,244 6,033 6,033
Other (1) 12,206 12,206 12,132 12,132
Revenues $ 198,533 $ $ 198,533 $ 190,884 $ $ 190,884
OPERATING PROFIT
U.S. Pharmaceutical and Specialty Solutions $ 2,488 $ (2 ) $ 2,486 $ 2,879 $ 296 $ 3,175
European Pharmaceutical Solutions 173 262 435 149 310 459
Medical-Surgical Solutions 401 86 487 280 123 403
Other (1) (2) 4,514 (3,542 ) 972 764 119 883
Operating profit 7,576 (3,196 ) 4,380 4,072 848 4,920
Corporate (377 ) (4 ) (381 ) (469 ) 19 (450 )
Income from continuing operations before interest expense and income taxes $ 7,199 $ (3,200 ) $ 3,999 $ 3,603 $ 867 $ 4,470
OPERATING PROFIT AS A % OF REVENUES
U.S. Pharmaceutical and Specialty Solutions 1.60 % 1.60 % 1.93 % 2.13 %
European Pharmaceutical Solutions 0.70 1.75 0.63 1.95
Medical-Surgical Solutions 6.42 7.80 4.64 6.68
Last updated: May 24, 2018